Theradiag Announces Its 2022 Full-Year Results and 2023 First ... - ACROFAN USA
| ALBIO Stock | EUR 2.60 0.08 2.99% |
Slightly above 62% of Biosynex's investor base is looking to short. The analysis of current outlook of investing in Biosynex suggests that many traders are alarmed regarding Biosynex's prospects. Biosynex's investing sentiment overview a quick insight into current market opportunities from investing in Biosynex. Many technical investors use Biosynex stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Biosynex |
Theradiag Announces Its 2022 Full-Year Results and 2023 First ... ACROFAN USA
Read at news.google.com
 |
Biosynex Fundamental Analysis
We analyze Biosynex's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biosynex using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biosynex based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Last Dividend Paid
Last Dividend Paid Comparative Analysis
Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
Biosynex Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biosynex stock to make a market-neutral strategy. Peer analysis of Biosynex could also be used in its relative valuation, which is a method of valuing Biosynex by comparing valuation metrics with similar companies.
Peers
Biosynex Related Equities
| ALEUP | Europlasma | 95.12 | ||||
| ALBPS | Biophytis | 3.45 | ||||
| IPH | Innate Pharma | 1.41 | ||||
| ALCLS | Cellectis | 3.11 |
Additional Tools for Biosynex Stock Analysis
When running Biosynex's price analysis, check to measure Biosynex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosynex is operating at the current time. Most of Biosynex's value examination focuses on studying past and present price action to predict the probability of Biosynex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosynex's price. Additionally, you may evaluate how the addition of Biosynex to your portfolios can decrease your overall portfolio volatility.